SamaCare, a workflow platform for suppliers providing specialty remedy, introduced it secured $17 million in an oversubscribed Sequence B funding spherical.
New investor Questa Capital led the spherical, with participation from current buyers South Park Commons and Vive Collective.
WHAT IT DOES
The California-based firm gives a cloud-based workflow automation platform to assist suppliers receive prior authorization for specialty drug drugs, verify enrollment, and confirm advantages. It additionally works with pharmaceutical corporations to offer knowledge analytics to assist enhance entry to their therapies.
The corporate will use the funds to increase its Script-to-Remedy Working System, which is able to leverage AI for administrative duties, create a post-prescription workflow, accumulate knowledge insights and improve collaboration between suppliers’ places of work.
“SamaCare plans to take a position the funds to construct the excellent Script-to-Remedy Working System, enhancing our specialty prior auth platform’s capabilities for sufferers, suppliers, and pharmaceutical corporations,” Syam Palakurthy, founder and CEO of SamaCare, instructed MobiHealthNews in an e mail.
“This implies constructing into our platform extra collaboration options, AI-based steerage, and knowledge insights that collectively allow our clients to make sure that sufferers overcome administrative and monetary obstacles to start out on remedy.”
MARKET SNAPSHOT
SamaCare closed a $12 million Sequence A spherical in 2022.
Different corporations providing workflow automation platforms embrace Cerner, which was acquired by enterprise software program big Oracle in 2021 for $28.3 billion, and Epic, which affords medical and administrative workflow instruments.
